Penumbra, Inc. (NYSE:PEN) Director Bridget O'rourke Sells 50 Shares

Penumbra, Inc. (NYSE:PEN - Get Free Report) Director Bridget O'rourke sold 50 shares of Penumbra stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $259.78, for a total transaction of $12,989.00. Following the sale, the director now owns 5,373 shares in the company, valued at approximately $1,395,797.94. This trade represents a 0.92% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Bridget O'rourke also recently made the following trade(s):

• On Thursday, May 15th, Bridget O'rourke sold 100 shares of Penumbra stock. The shares were sold at an average price of $286.15, for a total transaction of $28,615.00.
• On Tuesday, April 15th, Bridget O'rourke sold 50 shares of Penumbra stock. The shares were sold at an average price of $271.21, for a total transaction of $13,560.50.

Penumbra Trading Down 0.1%

NYSE:PEN traded down $0.26 during trading hours on Friday, hitting $256.75. The stock had a trading volume of 859,137 shares, compared to its average volume of 452,166. Penumbra, Inc. has a one year low of $148.00 and a one year high of $310.00. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.68 and a current ratio of 6.30. The company has a market cap of $9.94 billion, a price-to-earnings ratio of 242.22, a P/E/G ratio of 2.29 and a beta of 0.49. The business's 50 day moving average is $274.48 and its 200-day moving average is $267.56.

Penumbra (NYSE:PEN - Get Free Report) last issued its earnings results on Wednesday, April 23rd. The company reported $0.83 EPS for the quarter, beating the consensus estimate of $0.66 by $0.17. Penumbra had a net margin of 3.41% and a return on equity of 11.14%. The firm had revenue of $324.14 million during the quarter, compared to the consensus estimate of $315.72 million. During the same quarter in the prior year, the firm earned $0.41 earnings per share. The business's quarterly revenue was up 16.3% on a year-over-year basis. Sell-side analysts anticipate that Penumbra, Inc. will post 3.67 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Truist Financial boosted their price target on shares of Penumbra from $315.00 to $330.00 and gave the company a "buy" rating in a research report on Thursday, April 24th. Wells Fargo & Company boosted their target price on shares of Penumbra from $305.00 to $315.00 and gave the stock an "overweight" rating in a research note on Thursday, April 24th. Wall Street Zen raised shares of Penumbra from a "buy" rating to a "strong-buy" rating in a research note on Saturday, June 14th. Stifel Nicolaus set a $318.00 target price on shares of Penumbra and gave the stock a "buy" rating in a research note on Thursday, April 24th. Finally, Robert W. Baird boosted their target price on shares of Penumbra from $316.00 to $325.00 and gave the stock an "outperform" rating in a research note on Thursday, April 24th. Three research analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $302.40.

Institutional Investors Weigh In On Penumbra

Several large investors have recently bought and sold shares of PEN. Synergy Investment Management LLC bought a new stake in Penumbra in the first quarter valued at approximately $27,000. First Horizon Advisors Inc. boosted its holdings in shares of Penumbra by 404.8% in the first quarter. First Horizon Advisors Inc. now owns 106 shares of the company's stock valued at $28,000 after buying an additional 85 shares during the period. Hurley Capital LLC acquired a new position in shares of Penumbra in the fourth quarter valued at approximately $56,000. Huntington National Bank boosted its holdings in shares of Penumbra by 138.7% in the fourth quarter. Huntington National Bank now owns 265 shares of the company's stock valued at $63,000 after buying an additional 154 shares during the period. Finally, AlphaQuest LLC acquired a new position in shares of Penumbra in the first quarter valued at approximately $66,000. Institutional investors own 88.88% of the company's stock.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.